User Growth and Customer Base - Active individual users increased from less than 30,000 to over 5 million[14] - The number of active life science customers rose from 74 to 108[14] - The number of top-tier research hospitals served increased from 71 to 76[14] - The coverage of regulatory agencies and policymakers expanded from 14 to 19[14] - The number of clients for life sciences solutions grew to 108, an increase of 34 clients from the previous year[23] - The health management platform has over 5 million paid users who have made at least one purchase as of March 31, 2021[30] - The number of active clients increased from 74 to 108 within a year, with core pharmaceutical, biotech, and medical device clients growing from 55 to 80[29] Financial Performance - Total revenue for the fiscal year 2021 reached RMB 867.036 million, representing a year-on-year growth of 55.4%[21] - Revenue from health management solutions surged by 353.1% to RMB 252.129 million, compared to RMB 55.648 million in 2020[21] - Gross profit increased by 123.4% to RMB 327.336 million, with a gross margin of 37.8%, up 11.5 percentage points year-on-year[21][23] - The company reported an annual loss of RMB 3.695 billion, a 144.5% increase compared to RMB 1.511 billion in 2020[21] - Revenue increased by 55.4% from RMB 558.1 million for the fiscal year ended March 31, 2020, to RMB 867.0 million for the fiscal year ended March 31, 2021[32] - Revenue from life sciences solutions rose by 79.3% from RMB 102.8 million to RMB 184.3 million, driven by an increase in active customers from 74 to 108[32] - Revenue from health management platform and solutions surged by 353.1% from RMB 55.6 million to RMB 252.1 million, primarily due to increased income from platform-based solutions[32] Research and Development - The company aims to enhance real-world research to achieve inclusive precision medicine[19] - The company is focused on improving data infrastructure capabilities to support the healthcare industry's transition to data-driven intelligence[18] - The company has developed high-quality disease models to support precise diagnosis and efficient drug development[18] - The company aims to enhance data processing capabilities and deepen understanding of various disease areas while expanding its customer base and exploring international market opportunities[31] - The company plans to optimize disease mapping and produce research-grade insights and knowledge for various disease areas[31] Technology and Data Solutions - The company has established a COVID-19 big data intelligent platform in collaboration with a well-known research hospital in Wuhan[18] - The YiduCore data infrastructure supports high-quality data applications in various scenarios, enhancing the value of data for clients and partners[24] - YiduCore's data infrastructure covers over 500 medical institutions across more than 20 provinces in China, processing over 1.7 billion medical records from over 400 million patients[27] - The big data platform, launched in 2015, connects with existing hospital systems to provide insights for medical research, clinical diagnosis, and hospital management[143] - Life sciences solutions offer analytics-driven clinical development and real-world evidence-based research to pharmaceutical and biotechnology companies[144] - The health management platform provides personalized health management services, integrating traditional medical treatment with out-of-hospital care and lifestyle interventions[145] Governance and Compliance - The company is committed to complying with relevant laws and regulations, with no significant violations reported during the reporting period[64] - The company faces several risks, including the ability to manage growth and expansion, keep up with rapid technological changes, and comply with data protection laws[62] - The company has implemented a comprehensive anti-bribery and anti-corruption policy, ensuring compliance with relevant laws and regulations[156] - There were no judicial cases related to corruption, fraud, or money laundering during the reporting period[157] - The company has established a risk management framework that includes risk assessment, identification, analysis, response, and monitoring to enhance core competitiveness[153] Employee and Corporate Culture - The total number of employees as of March 31, 2021, was 1,201, with 834 located in Beijing, 146 in Shanghai, and 221 in other locations[54] - As of March 31, 2021, approximately 47% of employees have a medical background, and about 38% have a background in artificial intelligence and technology, representing increases of 33.1% and 17.0% year-over-year, respectively[55] - The company emphasizes employee health and safety, providing free annual health check-ups and adhering to national safety regulations, with no work-related fatalities reported during the period[186] - The company has established a comprehensive welfare system, including social security contributions for retirement, medical, unemployment, work injury, and housing funds, along with supplementary medical insurance covering five direct relatives[181] - The company promotes equal employment opportunities and opposes any form of employment discrimination based on gender, age, nationality, color, religion, or disability[180] Corporate Social Responsibility - The company has donated over RMB 6 million to various institutions for medical research, artificial intelligence research, education, and youth development during the reporting period[199] - The company received the "Caring Unit" honor from the Guizhou Poverty Alleviation Foundation for its active participation in poverty alleviation efforts[199] - The company continues to engage in poverty alleviation by procuring high-quality green agricultural products from Guizhou for the Spring Festival[200] - The company has implemented various training programs aimed at enhancing employee knowledge and skills, including general skills training and leadership training[198] - The company actively participates in corporate social responsibility initiatives, focusing on community support and development[199] Intellectual Property and Innovation - The company registered a total of 860 patents, with 249 new patents added during the reporting period[165] - The company emphasizes the importance of intellectual property protection and has established a patent management system to encourage innovation[165] - The company has obtained multiple information security management system certifications, including ISO/IEC 27001:2013 and ISO/IEC 27017:2015[159] - The company has established an information security committee responsible for overseeing all information security work[161] Leadership and Management - Yang Jing was appointed as CFO in September 2017 and President in January 2019, overseeing finance, legal, marketing, HR, operations, and investment activities[107] - Dr. Yan Jun has been the Chief Technology Officer since December 2017, responsible for the overall technology strategy and development of AI technologies[109] - The management team has extensive experience in technology and finance, with backgrounds in leading firms like Microsoft and GIC[107][109] - The company has a strong leadership team with key positions held by co-founders, including Mr. He Zhi as Chief Innovation Officer and Mr. Xu Jiming as Senior Vice President of Life Sciences Solutions[114]
医渡科技(02158) - 2021 - 年度财报